Search

Displaying results 5891 - 5900 of 10000 in total
  1. Drug

    SynKIR-110

    go.drugbank.com/drugs/DB17365
    Investigational

    SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).

  2. Drug

    PRX-ASL

    go.drugbank.com/drugs/DB17679
    Experimental

    PRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.

  3. Drug

    ATX-101

    go.drugbank.com/drugs/DB05780
    Investigational

    As a naturally occurring component of the human body, deoxycholate is considered a ‘biocompatible’ detergent that solubilizes fat in the small intestine. … ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits.

  4. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    Sofpironium is a "soft" anticholinergic analog of [glycopyrronium] that has been modified with a readily hydrolyzable ester moiety. … rapid metabolism to inactive metabolites after exerting activity at its target site.

  5. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...

  6. Drug

    Astaxanthin

    go.drugbank.com/drugs/DB06543
    Investigational

    Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. … It may be found in fish feed or some animal food as a color additive.

  7. Drug

    SAR443122

    go.drugbank.com/drugs/DB16492
    Investigational

    SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. NCT04469621 was studied in severe COVID-19 patients, while NCT05588843 is currently recruiting participants with ulcerative colitis. Additionally...

  8. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).

  9. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

  10. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]